Last reviewed · How we verify
A. Paniculata
Andrographis paniculata extract enhances immune function and reduces inflammatory markers through multiple phytochemical constituents.
Andrographis paniculata extract enhances immune function and reduces inflammatory markers through multiple phytochemical constituents. Used for Respiratory tract infections and common cold (Phase 3), Immune support and inflammation modulation.
At a glance
| Generic name | A. Paniculata |
|---|---|
| Sponsor | Vedic Lifesciences Pvt. Ltd. |
| Drug class | Herbal extract / Botanical immunomodulator |
| Modality | Small molecule |
| Therapeutic area | Immunology / Respiratory / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Andrographis paniculata (also known as Kalmegh) is a traditional Ayurvedic herb containing active compounds such as andrographolide and other diterpenes that modulate immune responses and suppress pro-inflammatory cytokines. The extract is believed to enhance natural killer cell activity and promote Th1-mediated immunity while reducing excessive inflammatory responses. These mechanisms support its use in respiratory and immune-related conditions.
Approved indications
- Respiratory tract infections and common cold (Phase 3)
- Immune support and inflammation modulation
Common side effects
- Gastrointestinal upset
- Allergic reactions
- Hepatotoxicity (rare)
Key clinical trials
- To Assess the Effect of 336 Days Exposure of Paractin® on Pain & Disease Progression in Patients Suffering From Osteoarthritis of Knee Joint. (NA)
- Comparison of the Effectiveness of Sambiloto Herbs (Andrographis Paniculata) and Brisk Walking Exercise on Blood Glucose of Obese Patients (NA)
- Comparison of the Effectiveness of Sambiloto Herbs (Andrographis Paniculata) and Brisk Walking Exercise on Blood Pressure of Obese Patients (NA)
- To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTI (PHASE3)
- Assessment of Efficacy of KAN-JANG® in Mild COVID-19 (PHASE2, PHASE3)
- Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19 (PHASE3)
- Assessment of the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate Osteoarthritis (NA)
- The Effect of Andrographis Paniculata to GLP-1, Fasting Insulin, Insulin 2-h Post OGTT, and HOMA-IR (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A. Paniculata CI brief — competitive landscape report
- A. Paniculata updates RSS · CI watch RSS
- Vedic Lifesciences Pvt. Ltd. portfolio CI